Roche Gains CE Mark Approval for Elecsys pTau217 Test
BASEL, Switzerland, May 12, 2026 Roche announced that it has received European CE Mark approval for Elecsys® plasma phosphorylated-tau...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
BASEL, Switzerland, May 12, 2026 Roche announced that it has received European CE Mark approval for Elecsys® plasma phosphorylated-tau...
Phoenix, AZ – October 27, 2025: Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company, has issued...
PARIS – October 24, 2025 Sanofi reported a 7.0% sales increase at constant exchange rates (CER) for Q3 2025,...
BURLINGTON, N.C. – October 23, 2025 Labcorp (NYSE: LH), a global leader in laboratory diagnostics, announced it will soon...
